Pharma News

pharma courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • New Therapy May Effectively Control HIV in Uganda
    20 February 2025

    New Therapy May Effectively Control HIV in Uganda

    A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
  • 18 February 2025
    Nemluvio of Gladerma granted marketing authorization in the United Kingdom and Switzerland
    Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumabs subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors
  • 18 February 2025
    Stanford researchers identify biological pathways associated with inherited cancer risk
    Thousands of single changes in the nucleotides that make up the human genome have been associated with an increased risk of developing cancer. But until now, its not been clear which are directly responsible for the uncontrolled cellular growth that is the hallmark of the disease and which are simply coincidences or minor players.
  • 18 February 2025
    MED-EL USA gets FDA approval for cochlear implant
    MED-EL USA announced that the U.S. Food and Drug Administration approved the new SONNET 3 audio processor for MED-EL cochlear implants. SONNET 3 is the companys lightest and smallest behind-the-ear audio processor and features integrated wireless direct streaming capabilities.
  • 17 February 2025
    Olpasiran associated with reducing bad cholesterol in Cardiovascular Disease
    The RNA inhibitor olpasiran significantly reduces a type of bad cholesterol thats associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a phase 2 trial. The study reported that higher doses of olpasiran lowered the type of cholesterol called lipoprotein a by more than 95 percent in participants with atherosclerotic cardiovascular disease.
  • 17 February 2025
    Personalised diet eases irritable bowel syndrome

    Michigan Medicine and Cleveland Clinic researchers have found that patients with irritable bowel syndrome were more likely to experience less abdominal pain if they followed a diet guided by the results of a blood test, compared to those who followed a sham elimination diet.

  • 17 February 2025
    Gene therapy for rare epilepsy shows promise in mice
    Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even sudden death.
  • 15 February 2025
    BMS melanoma drug failed in clinical trial
    Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag nivolumab and relatlimab-rmbw for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival.
  • 15 February 2025
    Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
    Pfizer Inc announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA talazoparib, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI enzalutamide, an androgen receptor pathway inhibitor ARPI, demonstrating a statistically significant and clinically meaningful improvement in overall survival OS compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer mCRPC, with or without homologous recombination repair HRR gene mutations.
  • 15 February 2025
    Breakthrough in Click Chemistry : Innovative Method Revolutionizes Drug Development

    Middle molecules with a molecular weight of more than 1,000 are difficult to synthesize due to multiple steps and time-consuming nature, demanding the development of a new approach that can overcome these disadvantages. Click chemistry has become an essential tool in applied chemistry due to its simplicity, efficiency, and versatility. This approach to chemical synthesis allows for quick and reliable joining of small molecules into larger, more complex structures, often with minimal side reactions and byproducts.

Subscribe to Pharma News